Known as Synera, which is marketed by Nuvo Research and ZARS Pharmaceutical Inc., this topical anesthetic patch is due to have a patent expiration on July 28, 2015. The generic ingredients of both Lidocaine CAS# 137-58-6, and Tetracaine CAS# 94-24-6 are projected to be sought after as researchers clamor to create generic alternatives of this efficacious patch. The unique convenience of Synera, or lidocaine and tetracaine, is it’s peel and stick feature. Approved for children ages 3 and up, this topical patch is designed to be an anesthetic to help numb intact skin prior to minor needle procedures. For a large population of children and adults, needle procedures are an unfortunate but necessary part of medical care. This procedure can be a major source of anxiety and pain, especially for children. The use of this friendly lidocaine and tetracaine patch makes procedures like the drawing of blood for lab tests or the administration of an I.V. for fluids more tolerable.
The doses of lidocaine and tetracaine in the Synera patch are comprised of 70 milligrams of lidocaine and 70 milligrams of tetracaine. Patients with a sensitivity to lidocaine, tetracaine, or para-aminobenzoic acid (PABA) should not use this patch. Adverse reactions from clinical studies were generally mild, and included reports of redness and swelling at the application site. The reactions went away on their own for all patients who received this lidocaine and tetracaine patch.
On February 2, 2012 Nuvo Research announced it’s U.S. launch of Synera as a heated topical patch. With both 70 milligrams each of lidocaine and tetracaine, this patch was designed to be safe and effectual as local dermal analgesia. Procedures which this patch is appropriate for includes superficial dermatological procedures like excisions, electrodessications and shave biopsies of skin lesions. The current push in the medical community for the use of safe anesthetic patches prior to painful needle procedures is growing. There is a substantial amount of U.S. physicians who perform interventional needle procedures in their everyday practice, such as knee drains, nerve blocks and epidurals. This novel lidocaine/tetracaine pain patch will appeal to the estimated 3,600 U.S. physicians who perform 50% of these 23 million interventional needle procedures.
LGM Pharma is a provider of both the lidocaine API and the tetracaine API for research and development purposes. Clients can be assured of total support throughout the entire R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.